Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.13
+4.3%		$0.17
$0.10
▼
$3.13
$780K2.074.32 million shs645,745 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.43
+5.1%		$2.18
$0.16
▼
$17.38
$2.91M1.841.97 million shs1.54 million shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.88
-0.5%		$3.84
$1.43
▼
$60.44
$2.75M1.8396,450 shs17,241 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.99
$1.06
$0.31
▼
$1.50
$2.57M1.13,208 shs773 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
+4.25%+3.42%-16.13%-48.31%-95.26%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+5.10%+1.27%-81.12%-81.61%-97.45%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-0.53%-9.18%-48.35%-59.40%-96.87%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-13.91%-23.26%-10.00%+41.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.13
+4.3%		$0.17
$0.10
▼
$3.13
$780K2.074.32 million shs645,745 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.43
+5.1%		$2.18
$0.16
▼
$17.38
$2.91M1.841.97 million shs1.54 million shs
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.88
-0.5%		$3.84
$1.43
▼
$60.44
$2.75M1.8396,450 shs17,241 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.99
$1.06
$0.31
▼
$1.50
$2.57M1.13,208 shs773 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
+4.25%+3.42%-16.13%-48.31%-95.26%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+5.10%+1.27%-81.12%-81.61%-97.45%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-0.53%-9.18%-48.35%-59.40%-96.87%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-13.91%-23.26%-10.00%+41.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.33
Hold$22.005,011.52% Upside
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
1.00
SellN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IMCC, VCNX, NXTS, and MBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/15/2026
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.17M0.02N/AN/A($0.49) per share-0.27
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$4.69 per shareN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/A$39.70 per shareN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K6.63N/AN/A($2.59) per share-0.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$1.75N/AN/AN/A-27.65%-585.96%-39.96%8/11/2026 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$33.56M-$17.98N/AN/AN/AN/AN/A-70.93%8/11/2026 (Estimated)
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-$4M-$114.15N/AN/AN/AN/A-145.15%-111.82%N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%N/A

Latest IMCC, VCNX, NXTS, and MBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$1.55N/AN/AN/AN/AN/A
5/14/2026Q1 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$2.3333-$3.54-$1.2067-$3.54N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.55
0.47
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.38
1.38
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.01
4.73
4.73
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
61.24%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1.10%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
6.52%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
3406.22 millionN/ANot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
207.10 million7.02 millionNot Optionable
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
21.45 million1.36 millionN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex (VCNX) Projected to Post Earnings on Monday
August 9 at 1:56 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949501
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
Vaccinex presents promising cancer treatment data at ASCO
May 29, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/vaccinex-presents-promising-cancer-treatment-data-at-asco-93CH-4104876
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025
May 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/vaccinex-inc-present-new-data-pepinemabs-role-enhancing-immune-responses-head-and-neck
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088645/34858/en/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting.html
AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65384714-abtherx-inc-abtherx-single-cell-technology-and-vaccinex-announce-collaboration-to-tackle-challenging-antibody-drug-targets-200.htm
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abtherx-single-cell-technology-vaccinex-100000437.html
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-report-new-clinical-data-on-pepinemab-in-enhancing-immunotherapy-1034603197
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025
April 21, 2025  |  quiverquant.comQ
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064665/34858/en/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr.html
Vaccinex director resigns, no disagreement cited
March 21, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/vaccinex-director-resigns-no-disagreement-cited-93CH-3937856
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
March 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaccinex-plans-nasdaq-exit-alzheimer-211545558.html
Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 8, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64767350-vaccinex-inc-vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market-399.htm
Vaccinex to delist common stock from Nasdaq
March 7, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-delist-common-stock-from-nasdaq-1034455385

New MarketBeat Followers Over Time

Media Sentiment Over Time

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$0.13 +0.01 (+4.25%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$0.13 0.00 (-0.77%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.43 +0.02 (+5.10%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$0.43 0.00 (-0.33%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Nexentis Technologies stock logo

Nexentis Technologies NASDAQ:NXTS

$1.88 -0.01 (-0.53%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$1.90 +0.02 (+1.06%)
As of 07:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.99 0.00 (0.00%)
As of 08/7/2026 03:16 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas